Archive
542 articles, sorted by publication time.
FDA approval moves Treg cell therapy from a scientific narrative into commercial testing; the next question is not only whether patients can benefit, but also whether Orca Bio has a manufacturing, sales, and risk story that public markets are willing to bear.
Anthropic is packaging Claude as a research workbench, aiming to let biomedical researchers handle data organization, model computation, and result traceability in the same environment. It may lower the computational barrier for research into rare diseases, but truly producing usable drugs remains separated by experimental validation, data quality, and regulatory trust.
Teams from Cambridge and Southampton are bringing viral genetic data and machine learning into the clinic; early trials show acceptable safety, but whether protection can be scaled up is the real test for this platform technology.
As the fervor around generative AI gradually recedes, the drug development industry is starting to ask harder questions: whether models can propose candidate molecules that can be synthesized, validated, and brought into clinical decision-making.
This approval is not about making the immune system attack tumors more aggressively, but about attempting to restore order after allogeneic stem cell transplantation: preserving the treatment’s anticancer force while reducing the long-term burden of chronic graft-versus-host disease.
After immunotherapy reshaped the liver cancer treatment landscape, the real challenge has shifted to how to design trials that physicians, patients, and regulators can trust. A new international consensus seeks to turn fragmented standards for endpoints, populations, and controls into an executable roadmap for clinical research.
An IDE authorization is not an endorsement of efficacy, but it does mean this cancer treatment technology has obtained regulatory permission to enter human testing; with data still limited, the real focus is how it will be validated safely and clearly.
A new clinical trial is moving an immunotherapy drug closer to patients, but currently available public information is limited; the real focus is not the announcement itself, but whether it can demonstrate safety, efficacy, and the appropriate patient population in a rigorous trial.
Singapore’s CytoMed is engineering gamma delta T cells into a cancer cell therapy that can be supplied by donors, seeking to bypass the costly and slow manufacturing bottleneck of personalized CAR-T; but the technology has only just entered early human trials, and still has a clinical path ahead before efficacy can be proven.
This is not simply a deal to expand a product catalog; it reflects how biopharmaceutical R&D is pulling reagents, analytical instruments, diagnostic technologies, and cell therapy manufacturing materials into a tighter infrastructure chain.
The first participant has received an injection, formally moving epigenetic reprogramming from animal models and the imagination of longevity science into human safety testing; its real challenge is not reversing age, but whether it can repair damaged vision without crossing the line.
Tsingke Biotech brought RNA drug discussions together through an industry salon. The announcement itself was understated, but it reflects how nucleic acid drug development is shifting from target imagination to the next stage of competition: delivery, quality, and clinical verifiability.